For Locally Advanced PCa, Add Radiation

Schieszer, John
September 2010
Renal & Urology News;Sep2010, Vol. 9 Issue 9, p24
The article offers information on the randomized international trial which reveals that standard treatment for men with advanced prostate cancer should be androgen deprivation therapy (ADT) and external beam radiation.


Related Articles

  • Higher Radiation Doses, Fewer Treatments.  // USA Today Magazine;Oct2011, Vol. 140 Issue 2797, p14 

    The article focuses on the results of a multicenter clinical trial which showed the efficacy and safety of higher doses of stereotactic body radiation therapy (SBRT) that involves fewer treatments to patients with low- to intermediate-risk prostate cancer.

  • Choline PET based dose-painting in prostate cancer - Modelling of dose effects. Niyazi, Maximilian; Bartenstein, Peter; Belka, Claus; Ganswindt, Ute // Radiation Oncology;2010, Vol. 5, p23 

    Background: Several randomized trials have documented the value of radiation dose escalation in patients with prostate cancer, especially in patients with intermediate risk profile. Up to now dose escalation is usually applied to the whole prostate. IMRT and related techniques currently allow...

  • Clinical trials in prostatic cancer–interpretations and misinterpretations. Newling, D W W // Prostate Cancer & Prostatic Diseases;1999, Vol. 2 Issue 3, p120 

    New agents and therapies in prostate cancer, as in other diseases, need to be accurately, comprehensively and logically developed. The golden standard, a prospective, randomised phase III study can only be carried out efficiently if phase I and phase II studies have been completed. The advent of...

  • Clinical Trial watch Prostate Cancer.  // Urology Times;Apr2003, Vol. 31 Issue 4, p62 

    Offers information on clinical trials relating to prostate cancer as of April 2003. Inclusion of a phase III randomized study of prostatectomy versus expectant management with palliative therapy in patients with clinically localized prostate cancer; Phase III randomized study of radical...

  • Risk-Based Management of Prostate Cancer. D'Amico, Anthony V. // New England Journal of Medicine;7/14/2011, Vol. 365 Issue 2, p169 

    The author discusses the results of a randomized trial by the Radiation Therapy Oncology Group which evaluated external-beam radiation therapy with or without 4 months of hormonal therapy in eligible men with a median age of 71 years and localized prostate cancer. The study concludes that...

  • The Current Role of Androgen Deprivation in Patients Undergoing Dose-Escalated External Beam Radiation Therapy for Clinically Localized Prostate Cancer. Smith, Michael J.; Akhtar, Naveed H.; Tagawa, Scott T. // Prostate Cancer (20903111);2012, p1 

    Purpose. To review existing literature on the role of androgen deprivation therapy (ADT) with dose escalated radiation therapy. Methods and Materials. A PubMed search was undertaken to identify relevant articles. Results. Multiple recent studies were identified examining the role of ADT in the...

  • Dose-Escalated Hypofractionated Intensity-Modulated Radiotherapy in High-Risk Carcinoma of the Prostate: Outcome and Late Toxicity. Thomson, David; Merrick, Sophie; Swindell, Ric; Coote, Joanna; Kelly, Kay; Stratford, Julie; Wylie, James; Cowan, Richard; Elliott, Tony; Logue, John; Choudhury, Ananya; Livsey, Jacqueline // Prostate Cancer (20903111);2012, p1 

    Background. The benefit of dose-escalated hypofractionated radiotherapy using intensity-modulated radiotherapy (IMRT) in prostate cancer is not established. We report 5-year outcome and long-term toxicity data within a phase II clinical trial. Materials and Methods. 60 men with predominantly...

  • Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer. Bonkhoff, Helmut // Prostate Cancer (20903111);2012, p1 

    Tissue markers may be helpful in enhancing prediction of radiation therapy (RT) failure of prostate cancer (PCa). Among the various biomarkers tested in Phase III randomized trials conducted by the Radiation Therapy Oncology Group, p16, Ki-67, MDM2, COX-2, and PKA yielded the most robust data in...

  • HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Li, H; Nakashima, H; Decklever, T D; Nace, R A; Russell, S J // Cancer Gene Therapy;Aug2013, Vol. 20 Issue 8, p478 

    Several clinical trials have shown that oncolytic herpes simplex virus type 1 (oHSV-1) can be safely administered to patients. However, virus replication in tumor tissue has generally not been monitored in these oHSV clinical trials, and the data suggest that its oncolytic potency needs to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics